2024
Treatment Access among Younger Medicaid Beneficiaries with Multiple Myeloma
Fiala M, Ji M, Shih Y, Huber J, Wang M, Johnson K, Gasoyan H, Wang R, Colditz G, Wang S, Chang S. Treatment Access among Younger Medicaid Beneficiaries with Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia 2024 DOI: 10.1016/j.clml.2024.07.017.Peer-Reviewed Original ResearchStem cell transplantationCell transplantationMyeloma therapyMultiple myelomaContinuous enrollmentAssociated with early detectionMulti-State Medicaid DatabaseMultivariate logistic regressionMyeloma patientsSolid tumorsHigh medical needMyeloma treatmentHematological cancersMyelomaPatientsMedicaid databaseClaims-based datasetScreening testAcute medical eventsLogistic regressionEarly detectionDiscontinuous enrollmentMedical needContinuous Medicaid coverageCancer diagnosisPD45-10 PROSTATE-SPECIFIC MEMBRANE ANTIGEN IMAGING FINDINGS AND SUBSEQUENT CLINICAL MANAGEMENT AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: A RETROSPECTIVE COHORT STUDY
Leapman M, Rabil M, Ghaffar U, Long J, Westvold S, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Kunst N, Wang S, Ma X, Gross C, Karnes R. PD45-10 PROSTATE-SPECIFIC MEMBRANE ANTIGEN IMAGING FINDINGS AND SUBSEQUENT CLINICAL MANAGEMENT AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: A RETROSPECTIVE COHORT STUDY. Journal Of Urology 2024, 211: e971. DOI: 10.1097/01.ju.0001008792.09108.b4.10.Peer-Reviewed Original ResearchPD08-10 EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: RESULTS OF DECISION ANALYTIC MODELING
Kunst N, Long J, Westvold S, Sprenkle P, Rabil M, Ghaffar U, Kim I, Saperstein L, Wang S, Ma X, Gross C, Leapman M. PD08-10 EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: RESULTS OF DECISION ANALYTIC MODELING. Journal Of Urology 2024, 211: e177. DOI: 10.1097/01.ju.0001008576.33217.96.10.Peer-Reviewed Original ResearchProstate cancerPatientsImmunotherapy utilization patterns in patients with advanced cancer and autoimmune disease
Li H, Huntington S, Gross C, Wang S. Immunotherapy utilization patterns in patients with advanced cancer and autoimmune disease. PLOS ONE 2024, 19: e0300789. PMID: 38625861, PMCID: PMC11020359, DOI: 10.1371/journal.pone.0300789.Peer-Reviewed Original ResearchConceptsAutoimmune diseasesImmunotherapy cycleFirst-lineNon-small cell lung cancerAdvanced cancerFirst-line immunotherapyOverall treatment toleranceCell lung cancerRenal cell carcinomaRetrospective cohort studyAssociated with lower oddsAdvanced melanomaCell carcinomaTreatment toleranceAbsolute contraindicationImmunotherapyConsensus guidelinesImprove cancer survivalLung cancerCohort studyClinical variablesCancer patientsAcademic centersPatientsIncidence rate
2020
Treatment patterns and survival in hepatocellular carcinoma in the United States and Taiwan
Lin YJ, Lin CN, Sedghi T, Hsu SH, Gross CP, Wang JD, Wang SY. Treatment patterns and survival in hepatocellular carcinoma in the United States and Taiwan. PLOS ONE 2020, 15: e0240542. PMID: 33052942, PMCID: PMC7556438, DOI: 10.1371/journal.pone.0240542.Peer-Reviewed Original ResearchGeographic Variations of Potentially Curative Treatments for Hepatocellular Carcinoma in the United States: A SEER-Medicare Study.
Cheng E, Hung P, Wang SY. Geographic Variations of Potentially Curative Treatments for Hepatocellular Carcinoma in the United States: A SEER-Medicare Study. Journal Of The National Comprehensive Cancer Network 2020, 18: 729-736. PMID: 32502978, DOI: 10.6004/jnccn.2020.7529.Peer-Reviewed Original ResearchConceptsHospital referral regionsCurative treatmentHepatocellular carcinomaIncidence of HCCCox proportional hazards modelSEER-Medicare studyPercutaneous ethanol injectionHepatitis B virusProportional hazards modelMore comorbiditiesSurgical resectionSurvival benefitTreatment patternsSEER-MedicareB virusRadiofrequency ablationEthanol injectionTreatment utilizationReferral regionsBetter survivalLower riskHazards modelPatientsSurvivalTreatmentAssociations Between End-of-Life Expenditures and Hospice Stay Length Vary by Clinical Condition and Expenditure Duration
Hung P, Hsu SH, Wang SY. Associations Between End-of-Life Expenditures and Hospice Stay Length Vary by Clinical Condition and Expenditure Duration. Value In Health 2020, 23: 697-704. PMID: 32540226, DOI: 10.1016/j.jval.2020.01.021.Peer-Reviewed Original ResearchConceptsChronic obstructive pulmonary diseaseCongestive heart failureEOL expendituresHospice staysEnd Results-Medicare dataLonger hospice staysObstructive pulmonary diseaseMonths of lifeDays of lifeDistinct disease trajectoriesPatient disease groupsCancer decedentsDifferential associationsHeart failureAggressive endPulmonary diseaseHospice lengthMedical covariatesCancer patientsHospice useDisease groupClinical conditionsLife careDisease trajectoriesPatients
2019
Income disparities in needle biopsy patients prior to breast cancer surgery across physician peer groups
Killelea BK, Herrin J, Soulos PR, Pollack CE, Forman HP, Yu J, Xu X, Tannenbaum S, Wang SY, Gross CP. Income disparities in needle biopsy patients prior to breast cancer surgery across physician peer groups. Breast Cancer 2019, 27: 381-388. PMID: 31792804, PMCID: PMC7512133, DOI: 10.1007/s12282-019-01028-4.Peer-Reviewed Original ResearchConceptsPhysician peer groupsLow-income patientsNeedle biopsyOdds ratioHigh-income patientsBreast cancer surgeryMethodsThe SurveillanceCancer surgeryIncome patientsMedicare databaseBiopsy patientsMedicare beneficiariesPatientsBiopsyLow incomeGroupDisparitiesReceiptEnd resultHigher incomeSurgeryPeer groupEpidemiologyFurther workGroup-level effectsLong term outcomes of sentinel lymph node biopsy for ductal carcinoma in situ
Hung P, Wang SY, Killelea BK, Mougalian SS, Evans SB, Sedghi T, Gross CP. Long term outcomes of sentinel lymph node biopsy for ductal carcinoma in situ. JNCI Cancer Spectrum 2019, 3: pkz052. PMID: 32337481, PMCID: PMC7049982, DOI: 10.1093/jncics/pkz052.Peer-Reviewed Original ResearchSentinel lymph node biopsyBreast-conserving surgeryBreast cancer mortalityLong-term outcomesDuctal carcinomaCancer mortalityEnd Results-Medicare datasetCompeting-risks survival analysisLymph node biopsyPopulation cohort dataNode biopsyOlder patientsSentinel lymphBreast conservationUS SurveillanceTerm outcomesSurvival analysisDCISPatientsStatistical significanceRoutine performanceBiopsySurgeryCarcinomaRecurrence
2018
Cost-Effectiveness Analyses of the 21-Gene Assay in Breast Cancer: Systematic Review and Critical Appraisal.
Wang SY, Dang W, Richman I, Mougalian SS, Evans SB, Gross CP. Cost-Effectiveness Analyses of the 21-Gene Assay in Breast Cancer: Systematic Review and Critical Appraisal. Journal Of Clinical Oncology 2018, 36: 1619-1627. PMID: 29659329, PMCID: PMC5978470, DOI: 10.1200/jco.2017.76.5941.Peer-Reviewed Original ResearchConceptsCost-effectiveness analysisChemotherapy useBreast cancerEarly-stage breast cancerStudy designIncremental cost-effectiveness ratioODX recurrence scoreHigh-risk patientsLow-risk patientsRisk of biasCost-effectiveness ratioCost-effectiveness estimatesIndustry fundingDistant recurrenceIndustry-funded studiesClinical characteristicsTumor characteristicsRecurrence scoreChemotherapy decisionsScore groupClinical practiceSystematic reviewODXPatientsCancerAssociations Between Sentinel Lymph Node Biopsy and Complications for Patients with Ductal Carcinoma In Situ
Killelea BK, Long JB, Dang W, Mougalian SS, Evans SB, Gross CP, Wang SY. Associations Between Sentinel Lymph Node Biopsy and Complications for Patients with Ductal Carcinoma In Situ. Annals Of Surgical Oncology 2018, 25: 1521-1529. PMID: 29516364, PMCID: PMC5928184, DOI: 10.1245/s10434-018-6410-0.Peer-Reviewed Original ResearchConceptsSentinel lymph node biopsyBreast-conserving surgeryLymph node biopsySLNB useNode biopsyWound infectionDuctal carcinomaUse of SLNBEnd Results-Medicare datasetIncidence of complicationsShort-term complicationsMonths of diagnosisOlder patientsSubsequent mastectomyInitial treatmentResultsOur sampleConsensus guidelinesHigh riskOlder womenComplicationsMultivariate analysisPatientsWomenDCISMastectomy
2017
Cost-Effectiveness of Multidisciplinary Management Program and Exercise Training Program in Heart Failure
Dang W, Yi A, Jhamnani S, Wang SY. Cost-Effectiveness of Multidisciplinary Management Program and Exercise Training Program in Heart Failure. The American Journal Of Cardiology 2017, 120: 1338-1343. PMID: 28842145, DOI: 10.1016/j.amjcard.2017.06.071.Peer-Reviewed Original ResearchConceptsMultidisciplinary management programIncremental cost-effectiveness ratioUsual careLife yearsHeart failureExercise training programHealthcare payer perspectiveCost-effectiveness ratioProbabilistic sensitivity analysesCost-effectiveness thresholdCurrent cost-effectiveness thresholdsPayer perspectiveHealthcare costsHealth outcomesTraining programSocietal perspectiveSignificant healthFinancial burdenPatientsManagement programETPFailureYearsCare
2016
Continuous Home Care Reduces Hospice Disenrollment and Hospitalization After Hospice Enrollment
Wang SY, Aldridge MD, Canavan M, Cherlin E, Bradley E. Continuous Home Care Reduces Hospice Disenrollment and Hospitalization After Hospice Enrollment. Journal Of Pain And Symptom Management 2016, 52: 813-821. PMID: 27697564, PMCID: PMC5154927, DOI: 10.1016/j.jpainsymman.2016.05.031.Peer-Reviewed Original ResearchConceptsHospice disenrollmentHospice enrollmentPatient characteristicsContinuous home careCHC utilizationMinority of patientsHome careMore comorbiditiesMultivariable analysisMultivariable modelHospice carePatientsHospitalizationService MedicareHospice agenciesHospiceDisenrollmentExpensive careStudy periodCareEnrollmentAssociationComorbiditiesCancer
2015
Preoperative Breast Magnetic Resonance Imaging and Contralateral Breast Cancer Occurrence Among Older Women With Breast Cancer
Wang SY, Long JB, Killelea BK, Evans SB, Roberts KB, Silber A, Gross CP. Preoperative Breast Magnetic Resonance Imaging and Contralateral Breast Cancer Occurrence Among Older Women With Breast Cancer. Journal Of Clinical Oncology 2015, 34: 321-328. PMID: 26628465, PMCID: PMC4872032, DOI: 10.1200/jco.2015.62.9741.Peer-Reviewed Original ResearchConceptsContralateral breast cancerPreoperative magnetic resonance imagingMagnetic resonance imagingBreast cancerCBC eventsMRI useOlder womenPreoperative breast magnetic resonance imagingOccult contralateral breast cancerResonance imagingStage IIEarly-stage breast cancerPreoperative MRI useBreast magnetic resonance imagingBreast cancer occurrenceSEER-Medicare databaseImpact of detectionDetection rateCumulative incidenceCancer occurrenceStage ICancerPropensity scoreWomenPatientsThe Role of Patient Factors, Cancer Characteristics, and Treatment Patterns in the Cost of Care for Medicare Beneficiaries with Breast Cancer
Xu X, Herrin J, Soulos PR, Saraf A, Roberts KB, Killelea BK, Wang SY, Long JB, Wang R, Ma X, Gross CP. The Role of Patient Factors, Cancer Characteristics, and Treatment Patterns in the Cost of Care for Medicare Beneficiaries with Breast Cancer. Health Services Research 2015, 51: 167-186. PMID: 26119176, PMCID: PMC4722219, DOI: 10.1111/1475-6773.12328.Peer-Reviewed Original ResearchConceptsBreast cancer careHospital referral regionsCancer careMedicare expendituresBreast cancerRadiation therapyTreatment factorsMean Medicare expendituresEnd Results-MedicareSpecific treatment modalitiesContribution of patientCost of careHighest spending quintilePatient factorsTreatment patternsTumor characteristicsCancer characteristicsTreatment modalitiesReferral regionsMedicare beneficiariesQuintilePatientsCancerCareTherapy
2012
Network Meta-analysis of Margin Threshold for Women With Ductal Carcinoma In Situ
Wang SY, Chu H, Shamliyan T, Jalal H, Kuntz KM, Kane RL, Virnig BA. Network Meta-analysis of Margin Threshold for Women With Ductal Carcinoma In Situ. Journal Of The National Cancer Institute 2012, 104: 507-516. PMID: 22440677, PMCID: PMC3916966, DOI: 10.1093/jnci/djs142.Peer-Reviewed Original ResearchConceptsIpsilateral breast tumor recurrenceBreast-conserving surgeryRisk of IBTRNegative marginsPositive marginsDuctal carcinomaOdds ratioBreast tumor recurrenceNegative surgical marginsNetwork Meta-AnalysisMixed treatment comparisonMargin thresholdIBTR eventsDCIS patientsMargin statusSurgical marginsTumor recurrenceMeta-regression techniquesReduced riskLower riskPatientsPubMed databaseCosmetic constraintsMeta-AnalysisRadiotherapy
2010
The Impact of Surgery, Radiation, and Systemic Treatment on Outcomes in Patients With Ductal Carcinoma In Situ
Kane RL, Virnig BA, Shamliyan T, Wang SY, Tuttle TM, Wilt TJ. The Impact of Surgery, Radiation, and Systemic Treatment on Outcomes in Patients With Ductal Carcinoma In Situ. JNCI Monographs 2010, 2010: 130-133. PMID: 20956816, PMCID: PMC5161061, DOI: 10.1093/jncimonographs/lgq022.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, Intraductal, NoninfiltratingChemotherapy, AdjuvantCombined Modality TherapyDisease ProgressionFemaleHumansIncidenceMastectomyMastectomy, SegmentalNeoplasm Recurrence, LocalNeoplasms, Second PrimaryPrognosisRadiotherapy, AdjuvantRandomized Controlled Trials as TopicTamoxifenTreatment OutcomeConceptsBreast-conserving surgeryDuctal carcinomaInvasive carcinomaWhole breast radiation therapyImpact of surgeryTerms of recurrenceInvasive recurrenceRecurrent DCISDCIS recurrenceSystemic treatmentObservational studyRadiation therapyEquivalent outcomesCarcinomaMastectomyRecurrenceDCISSurgeryTamoxifenLower ratesOutcomesWomenLumpectomyPatientsMEDLINEIncorporating margin status information in treatment decisions for women with ductal carcinoma in situ: a decision analysis
Wang SY, Kuntz K, Tuttle T, Kane R. Incorporating margin status information in treatment decisions for women with ductal carcinoma in situ: a decision analysis. Breast Cancer Research And Treatment 2010, 124: 393-402. PMID: 20848183, DOI: 10.1007/s10549-010-1166-7.Peer-Reviewed Original ResearchMeSH KeywordsBreast NeoplasmsCarcinoma, Intraductal, NoninfiltratingDecision Support TechniquesFemaleHumansMarkov ChainsMastectomy, SegmentalMiddle AgedNeoplasm Recurrence, LocalPatient PreferencePatient SelectionQuality-Adjusted Life YearsRadiotherapy, AdjuvantRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeConceptsBreast-conserving surgeryQuality-adjusted life yearsRadiation therapyMargin statusDuctal carcinomaRT side effectsDecision-analytic Markov modelOne-way sensitivity analysesImportance of patientsProbabilistic sensitivity analysesDCIS treatmentInvasive recurrenceSalvage mastectomyOptimal treatmentHypothetical cohortTreatment decisionsLifetime horizonSide effectsLife yearsDCISPatientsWomenCarcinomaTreatment